Biotech | 01 April 2022
USFDA seeks more analysis on Merck’s BLA for Vaxneuvance
No new studies have been requested
No new studies have been requested
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Air purification system achieves Intertek zero ozone certification
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Dupixent peak sales ambition raised to more than €13 billion
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
Subscribe To Our Newsletter & Stay Updated
